Found it Tim,here it is:
NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS
FOR: PROCYON BIOPHARMA INC.
ASE SYMBOL: PBP
SEPTEMBER 21, 1999
Procyon BioPharma Inc. Announces Appointment of Hans
Mader as President and CEO: Company Moves Head Office to
Montreal
LONDON, ONTARIO--Dr. Chandra Panchal, Chairman of the Board of
Procyon BioPharma Inc., announced today the appointment of Mr.
Hans Mader as President and CEO. The Company also announced that
it will be moving its head office to Montreal in order to benefit
from the synergies of the vibrant biotech environment in the
region.
Mr. Mader has had many years experience with leading firms in the
pharmaceutical industry in Canada, the U.S.A and Europe, most
recently as the Head of Global Marketing Services at the Head
Office of Novartis Pharma in Switzerland. Prior to his
appointment there, he directed the merger of Ciba-Geigy and Sandoz
in Canada and served as CEO of Sandoz and then as President and
CEO of the resulting company, Novartis Pharmaceuticals Inc.
Canada, with $300 million a year in sales and approximately 1,000
employees.
While at Novartis, Mr. Mader succeeded in attracting major
research projects and investments to Canada. At Sandoz, Mr. Mader
also held senior marketing positions and successfully launched
several new products as well as innovative marketing campaigns.
Mr. Mader is a member of the Board of Canada's Research-Based
Pharmaceutical Companies (formerly the Pharmaceutical
Manufacturers' Association of Canada) and active in a number of
its committees.
"Procyon has reached a state in its development where it believes
the experience of a seasoned pharmaceutical executive can take the
Company to the next level of commercial development and
partnering. We are delighted that Hans Mader has decided to join
us to take on this challenge," stated Dr. Panchal who has served
as the Company's Chairman, President and CEO since co-founding it
in 1989. Dr. Panchal will take on the position of Executive
Vice-President and Chief Scientific Officer in order to devote his
full attention to the development of the company's technologies
and to the identification of new technology platforms and
international collaborations.
Mr. Mader's appointment becomes effective as of today. "In
returning to Canada, I have had the opportunity to look at several
biotech companies," he said, "and I have chosen Procyon because of
its remarkably innovative technologies for the treatment of cancer
and because it represents a well balanced portfolio with products
that are close to market as well as proprietary R&D platforms for
future growth. My goal is to commercialize this Company's
excellent scientific pipeline," he added.
Procyon's laboratory facilities will be located in Montreal's
Biotechnology Research Institute and its administrative offices
will be situated in the West Island of Montreal. Scientific and
administrative staff levels will remain approximately the same and
some active research collaboration in London, Ont. will be
maintained.
Procyon BioPharma Inc. is a publicly listed, biopharmaceutical
company focused principally on advancing two powerful platform
technologies that have the potential to treat, diagnose and
prevent cancer. Procyon's Prostate Secretory Protein (PSP94) is a
naturally occurring human protein that has the potential to treat
prostate cancer by inhibiting abnormal prostate cell growth.
Antinuclear Autoantibodies (ANAs) bind specifically to multiple
cancer cell types strongly enhancing the immune response to cancer
cells. Procyon also has two late-stage products in its pipeline:
FIBROSTAT(TM), a topical cream for the management of newly formed
scars following surgery or burns and COLOPATH(TM), a rapid,
non-invasive screening test for colorectal cancer. Procyon's
shares trade on the Alberta Stock Exchange under the ticker
symbol, PBP.
The Alberta Stock Exchange has neither approved nor disapproved of
the information contained herein.
Come on people,if this is not good news then I am very bewildered,welcome Mr.Mader and continued success to Dr.Panchal. |
